Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults.
Excitotoxicity, defined as excessive exposure to the neurotransmitter glutamate or overstimulation of its membrane receptors, has been implicated as one of the key factors contributing to neuronal injury and death in a wide range of both acute and chronic neurologic disorders. Excitotoxic cell death is due, at least in part, to excessive activation of N-methyl-D-aspartate (NMDA)-type glutamate receptors and hence excessive Ca2+ influx through the receptor's associated ion channel. Physiological NMDA receptor activity, however, is also essential for normal neuronal function; potential neuroprotective agents that block virtually all NMDA receptor activity will very likely have unacceptable clinical side effects. For this reason many NMDA receptor antagonists have disappointingly failed advanced clinical trials for a number of diseases including stroke and neurodegenerative disorders such as Huntington's disease. In contrast, studies in my laboratory were the first to show that memantine, an adamantane derivative, preferentially blocks excessive NMDA receptor activity without disrupting normal activity. Memantine does this through its action as an open-channel blocker; it enters the receptor-associated ion channel preferentially when it is excessively open, and, most importantly, its off-rate is relatively fast so that it does not substantially accumulate in the channel to interfere with normal synaptic transmission. Past clinical use for other indications has demonstrated that memantine is well tolerated, and it has recently been approved in both Europe and the USA for the treatment of dementia of the Alzheimer's type. Clinical studies of the safety and efficacy of memantine for other neurological disorders, including glaucoma and other forms of dementia, are currently underway. A series of second-generation memantine derivatives are currently in development and may prove to have even greater neuroprotective properties than does memantine. These second-generation drugs take advantage of the fact that the NMDA receptor has other modulatory sites, in addition to its ion channel, that could potentially be used for safe but effective clinical intervention.
Lipton
Stuart A
SA
The Burnham Institute, and the University of California, San Diego, La Jolla, California 92037, USA. slipton@burnham.org
D000818:Animals; D001921:Brain / Q000187:drug effects; D002986:Clinical Trials as Topic; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use*; D006801:Humans; D008559:Memantine / Q000627:therapeutic use*; D008959:Models, Neurological; D019636:Neurodegenerative Diseases / Q000188:drug therapy*; D009498:Neurotoxins / Q000627:therapeutic use; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors*
D018691:Excitatory Amino Acid Antagonists; D009498:Neurotoxins; D016194:Receptors, N-Methyl-D-Aspartate; D008559:Memantine
Physiol Rev. 1994 Jul;74(3):723-60
8036251
Clin Neurosci. 1997;4(5):270-3
9292254
Neuron. 1995 Oct;15(4):961-73
7576644
Vision Res. 1997 Dec;37(24):3483-93
9425525
J Neurosci. 1993 Jun;13(6):2651-61
7684776
AMA Arch Ophthalmol. 1957 Aug;58(2):193-201
13443577
Proc Natl Acad Sci U S A. 2000 May 23;97(11):6161-6
10811898
Trends Neurosci. 1993 Dec;16(12):527-32
7509524
Nat Neurosci. 2002 Nov;5 Suppl:1039-42
12403981
Eur J Pharmacol. 1990 Aug 21;185(1):19-24
2226632
Neuroreport. 1995 Apr 19;6(6):942-4
7612888
Semin Neurol. 1998;18(4):485-92
9932619
Curr Opin Neurol Neurosurg. 1993 Aug;6(4):588-96
8400474
Trends Neurosci. 2002 Sep;25(9):474-80
12183209
Nature. 1970 Aug 8;227(5258):609-11
5464249
Trends Pharmacol Sci. 1996 Jun;17(6):227-33
8763201
J Neurochem. 1992 Oct;59(4):1211-20
1402878
Neurology. 1992 Jul;42(7):1403-5
1620355
Prog Brain Res. 1998;118:73-82
9932435
Ann Neurol. 1993 Apr;33(4):403-7
8098195
Drugs R D. 1999 Jan;1(1):3-8
10565968
Nature. 1993 Aug 12;364(6438):626-32
8394509
Int J Geriatr Psychiatry. 1999 Feb;14(2):135-46
10885864
Neuropharmacology. 1999 Jun;38(6):735-67
10465680
Vision Res. 1998 May;38(10):1489-94
9667013
JAMA. 1999 Jan 27;281(4):306-8
9929066
Amino Acids. 2000;19(1):133-49
11026482
Semin Ophthalmol. 1999 Sep;14(3):152-8
10790579
J Neurosci. 1992 Nov;12(11):4427-36
1432103
JAMA. 2001 Apr 4;285(13):1719-28
11277826
Proc Natl Acad Sci U S A. 1998 May 12;95(10):5773-8
9576960
Vis Neurosci. 1999 Jan-Feb;16(1):45-52
10022477
Drugs Aging. 2001;18(10):717-24
11735619
Cell Calcium. 1998 Feb-Mar;23(2-3):165-71
9601612
Neuroscience. 1998 Oct;86(4):1121-32
9697119
J Physiol. 1997 Feb 15;499 ( Pt 1):27-46
9061638
Proc Natl Acad Sci U S A. 1991 Jul 15;88(14):6368-71
1648740
Invest Ophthalmol Vis Sci. 1995 Apr;36(5):774-86
7706025
Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3974-9
11904443
N Engl J Med. 1994 Mar 3;330(9):613-22
7905600
Nat Neurosci. 2000 Jan;3(1):15-21
10607390
N Engl J Med. 2003 Apr 3;348(14):1333-41
12672860
Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7162-6
7638161
J Neurochem. 1998 Sep;71(3):946-59
9721720
J Neuropathol Exp Neurol. 1969 Jul;28(3):455-74
5788942
Invest Ophthalmol Vis Sci. 1996 Jul;37(8):1618-24
8675405
Stroke. 2002 Jul;33(7):1834-9
12105362
Nature. 1987 Feb 5-11;325(6104):529-31
2433595
Lancet. 2000 Jun 3;355(9219):1949-54
10859040
Eur J Pharmacol. 1989 Aug 3;166(3):591-2
2553441
Curr Drug Targets. 2001 Sep;2(3):241-71
11554551